ACR Appropriateness Criteria s Advanced Stage Endometrial Cancer

Objectives: Patients with advanced stage endometrial carcinoma constitute a heterogeneous group of patients with different stages, tumor histologic types, and involved sites. Hysterectomy, bilateral salpingo-ophorectomy, and surgical staging are the cornerstone of surgical management in these patients. The optimal adjuvant therapy is yet to be established. An expert panel was convened to reach consensus on the most appropriate management options in this group of patients. Methods: The American College of Radiology Appropriateness Cri- teria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the appli- cation of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Results: Four clinical variants were developed to address common scenarios in the management of women with advanced-stage endometrial carcinoma. Group members reached consensus on the appro- priateness of specific evaluation and treatment approaches with numerical ratings. Conclusions: In combining available medical literature and expert opinions, this manuscript may serve as an aid for other practitioners in the appropriate management of women with advanced-stage endo- metrial carcinoma. Am J preliminary results of another GOG study presented The study randomized patients to versus a for In this study reported that

[1]  R. Barakat,et al.  Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer. , 2013, Gynecologic oncology.

[2]  A. Secord,et al.  A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. , 2013, Gynecologic oncology.

[3]  W. Small,et al.  A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418. , 2012, International journal of radiation oncology, biology, physics.

[4]  D. Miller,et al.  Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study , 2012 .

[5]  L. Levy,et al.  Vaginal motion and bladder and rectal volumes during pelvic intensity-modulated radiation therapy after hysterectomy. , 2012, International journal of radiation oncology, biology, physics.

[6]  J. Rownd,et al.  American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. , 2012, Brachytherapy.

[7]  P. Zola,et al.  Chemotherapy Plus Radiation in Advanced-Stage Endometrial Cancer , 2011, International Journal of Gynecologic Cancer.

[8]  S. Pignata,et al.  Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study , 2011, Oncology.

[9]  Matthew J. Pearson,et al.  A Phase I Study using low-dose fractionated whole abdominal radiotherapy as a chemopotentiator to full-dose cisplatin for optimally debulked stage III/IV carcinoma of the endometrium. , 2011, Gynecologic oncology.

[10]  B. Goff,et al.  Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. , 2011, American journal of obstetrics and gynecology.

[11]  L. Downs,et al.  A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. , 2011, Gynecologic oncology.

[12]  Jason D. Wright,et al.  Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. , 2011, Obstetrics and gynecology.

[13]  P. Zola,et al.  Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. , 2010, European journal of cancer.

[14]  K. Dusenbery,et al.  A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma. , 2010, Gynecologic oncology.

[15]  H. Putter,et al.  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.

[16]  L. Ramondetta,et al.  Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. , 2009, Gynecologic oncology.

[17]  A. Secord,et al.  A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. , 2009, Gynecologic oncology.

[18]  S. Pecorelli Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .

[19]  D. Cella,et al.  A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. , 2009, Gynecologic oncology.

[20]  P. Grigsby,et al.  Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. , 2009, Gynecologic oncology.

[21]  Joan L. Walker,et al.  Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study. , 2009, Gynecologic oncology.

[22]  A. Fortin,et al.  Clinical outcome of adjuvant treatment of endometrial cancer using aperture-based intensity-modulated radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[23]  M. Einstein,et al.  Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). , 2008, Gynecologic oncology.

[24]  A. Mariani,et al.  Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. , 2007, Gynecologic oncology.

[25]  M. Carey,et al.  Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. , 2007, International journal of radiation oncology, biology, physics.

[26]  J. Cooper,et al.  Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. , 2006, Gynecologic oncology.

[27]  P. Zola,et al.  Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial , 2006, British Journal of Cancer.

[28]  M. Hendrickson,et al.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers , 2006, British Journal of Cancer.

[29]  P. Maisonneuve,et al.  Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[30]  J. Thigpen,et al.  Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Warren D'Souza,et al.  Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. , 2005, International journal of radiation oncology, biology, physics.

[32]  M. Maiman,et al.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[33]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  O. Gómez-Marín,et al.  Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. , 2004, Gynecologic oncology.

[35]  P. Franzone,et al.  Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. , 2004, Gynecologic oncology.

[36]  R. Broaddus,et al.  Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. , 2003, Gynecologic oncology.

[37]  John C Roeske,et al.  Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. , 2003, International journal of radiation oncology, biology, physics.

[38]  M. J. Webb,et al.  Stage IIIC endometrioid corpus cancer includes distinct subgroups. , 2002, Gynecologic oncology.

[39]  John C Roeske,et al.  Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. , 2002, International journal of radiation oncology, biology, physics.

[40]  A. Mundt,et al.  Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. , 2001, International journal of radiation oncology, biology, physics.

[41]  A. Mundt,et al.  Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[42]  J. Roeske,et al.  Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. , 2000, International journal of radiation oncology, biology, physics.

[43]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. , 2000 .

[44]  G. Sutton,et al.  FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. , 1999, Gynecologic oncology.

[45]  A. Mundt,et al.  The significance of adnexal involvement in endometrial carcinoma. , 1999, Gynecologic oncology.

[46]  S. Liao,et al.  A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a Gynecologic Oncology Group pilot study. , 1996, Gynecologic oncology.

[47]  B. Corn,et al.  Pathologic stage III endometrial carcinoma: Significance of extrauterine sites , 1996 .

[48]  M. Ranney,et al.  Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.